The rules around compounded semaglutide changed.
If you started on a compounded GLP-1 in 2023 or 2024, the route you used to get it likely no longer exists. The FDA pulled semaglutide off the official shortage list on February 21, 2025, and on April 30, 2026 it proposed permanently barring 503B outsourcing facilities from making it at all. Compounded semaglutide is still legally available, but only through narrower channels, and the difference between a legitimate prescription and a sketchy copy of one matters more than ever.
🔑 Key Takeaways
- Compounded semaglutide is not banned, but the FDA shortage exemption that made it widely available ended in February 2025.
- Only 503A pharmacies can still legally fill compounded semaglutide, and only for patients with a documented clinical reason a standard dose will not work.
- Real 2026 pricing through legitimate telehealth lands between $150 and $400 per month, including the visit, the medication, and shipping.
- Anything sold without a prescription, marked "research" only, or shipped from outside the US is not legally compounded semaglutide.
- MEDVi and Yucca Valley Pharmacy are the two telehealth routes most readers find genuinely usable in May 2026.
What compounded semaglutide actually is
Compounded semaglutide is a custom-made version of the same active ingredient in Ozempic and Wegovy. A licensed compounding pharmacy mixes it from raw semaglutide API into an injectable, usually with bacteriostatic water and sometimes vitamin B12. It is not a generic. It is not made by Novo Nordisk. It is a prescription product made one batch at a time by a pharmacy operating under either Section 503A or Section 503B of the Federal Food, Drug, and Cosmetic Act.
The reason compounded semaglutide existed at scale from 2022 through early 2025 is straightforward. Demand for Ozempic and Wegovy exceeded supply, the FDA listed semaglutide as in shortage, and federal law lets pharmacies copy a drug while it sits on that list. Once the shortage ended, the legal cover ended with it.
The 2026 legal status, in one paragraph
Compounded semaglutide is legal in narrow circumstances and illegal in most. The FDA declared the semaglutide shortage resolved in February 2025. Wind-down deadlines for compounders ran through 2025. In April 2026, the FDA proposed adding semaglutide to a permanent exclusion list for 503B outsourcing facilities, with a public comment period open through June 29, 2026. As of May 2026, only 503A pharmacies can fill compounded semaglutide, and only when a prescriber documents that a standard FDA-approved dose cannot meet the patient's clinical need. Anyone selling "compounded semaglutide" without a prescription is selling something else.
503A vs 503B: why this distinction now decides everything
Before 2025, both pathways supplied compounded semaglutide. After the shortage ended, only one survived in any meaningful way.
| Pathway | Who | Allowed in 2026 | What it means for you |
|---|---|---|---|
| 503A pharmacy | Patient-specific compounder filling individual prescriptions | Yes, for non-standard doses with documented clinical need | This is the path almost every legitimate telehealth clinic uses today. |
| 503B outsourcing facility | Large-scale compounder supplying clinics in bulk | No, and the FDA has proposed making this permanent | If your clinic still claims a 503B supply, ask which one and verify directly. |
| Brand manufacturer | Novo Nordisk (Ozempic, Wegovy) | Yes, fully approved | Highest cost, lowest friction, most predictable supply. |
The "non-standard dose" loophole is doing most of the work in 2026. A 503A pharmacy can still legally produce compounded semaglutide if the prescription specifies a strength or formulation that is not commercially available, and the prescriber documents why. In practice this is how telehealth clinics structure their protocols, with personalized titration steps that fall between the brand-product strengths.
Compounded semaglutide pricing vs brand Ozempic and Wegovy
The price gap is the reason this market exists at all.
| Option | Monthly cost (2026) | What is included |
|---|---|---|
| Compounded semaglutide via telehealth | $150 to $400 | Visit, medication, shipping, dose adjustments |
| Wegovy (brand, no insurance) | ~$1,350 | Medication only, retail pharmacy |
| Ozempic (brand, no insurance) | ~$900 to $1,000 | Medication only, retail pharmacy |
| Wegovy with NovoCare direct pay | $499 | All doses, manufacturer self-pay program |
| Insurance with prior auth approved | $25 to $75 copay | Highly dependent on plan and BMI criteria |
For uninsured patients, compounded semaglutide remains the cheapest supervised path. For insured patients meeting Wegovy's BMI criteria, brand is usually cheaper after copay. If insurance denies you, the manufacturer self-pay program at $499 is the new mid-tier option to know about. We cover the full price ladder in our breakdown of GLP-1 cost options without insurance.
How to actually get compounded semaglutide in 2026
The route most readers end up on is telehealth. A doctor or NP licensed in your state evaluates you over video, writes a prescription if you qualify, and a partnered 503A pharmacy ships the vial or pen. No retail pharmacy involved.
The two telehealth options most readers use today
MEDVi is the route we point readers to first. They prescribe compounded semaglutide and tirzepatide along with brand Wegovy and Zepbound, include dietitian support and 24/7 messaging, and tend to land on the lower end of the $150 to $400 range. The intake takes about ten minutes.
Yucca Valley Pharmacy is the alternative. They focus specifically on personalized semaglutide and tirzepatide protocols, with the dosing flexibility a 503A pharmacy can legally offer. Useful if you want a more pharmacist-led conversation than a glossy clinic flow.
Ro and Hims also prescribe in this space. Both work fine. Pricing is comparable. The intake is similar. The reason we lean MEDVi first is the included dietitian visits and the lower entry tier.
Whichever route you pick, the legitimate version of this product comes with a prescription, a real pharmacy name printed on the vial, and a Certificate of Analysis available on request. If any of those are missing, you are not buying compounded semaglutide. You are buying something marketed as it.
Dose flexibility: the real reason 503A still works
Brand Wegovy comes in fixed steps: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg weekly. For a meaningful slice of patients, those steps are too aggressive. Side effects spike on the jump from 0.5 to 1 mg, or from 1.7 to 2.4 mg. A 503A compounded protocol can land you at, say, 0.75 mg or 1.25 mg for a few weeks before the next step. That intermediate titration is what makes compounded semaglutide tolerable for patients who could not stay on the brand schedule.
This is also the documentation a prescriber leans on when justifying compounding under 2026 rules. The prescription has to specify a strength or formulation that is not commercially available, with a clinical reason in the chart. "Patient experienced intolerable nausea on the standard 1 mg step, requires intermediate titration" is the kind of note that keeps a prescription legal.
What about B12 in compounded semaglutide?
Many compounded semaglutide formulations include cyanocobalamin, the same B12 used in injectable form for years. Pharmacies originally added it to argue the combination was not "essentially a copy" of brand semaglutide. The FDA closed that argument in 2026: if the route is the same and both APIs sit within 10% of standard strengths, the combination still counts as a copy. B12 in the vial is fine for the patient, but it does not by itself make a compounded prescription legal.
Red flags: how to spot a fake compounded semaglutide source
- No prescription required. Real compounded semaglutide is a prescription product, period. "Just add to cart" is illegal.
- Sold as research material. Anything labeled for non-human use is not the same product, even if the label says "semaglutide."
- Shipped from outside the US. International "semaglutide" usually contains semaglutide acetate, an unapproved salt form with no clinical data.
- No pharmacy name on the vial. A legitimate 503A vial lists the compounding pharmacy, the lot number, and the beyond-use date.
- No Certificate of Analysis available. Reputable pharmacies will share a COA on request showing identity, purity, and sterility testing.
- Prices below $100/month with no clinic visit. Real telehealth runs $150+ once you include the medical evaluation. Anything dramatically cheaper is either gray-market or counterfeit.
- Marketplaces and social DMs. The FDA logged over 455 adverse events tied to semaglutide products in 2025, many of them sourced this way.
How to verify a compounded semaglutide source is real
- Confirm the pharmacy name. Search the state pharmacy board for an active 503A license.
- Ask for the prescriber's name and license number. A real telehealth clinic will give you both.
- Request the COA for your specific lot. The document should show identity (semaglutide, not acetate), assay percentage, and sterility results.
- Check the vial for a beyond-use date no more than 90 days out. Compounded sterile injections do not have multi-year shelf lives.
- If anything on the label is missing or vague, do not inject it.
Compounded semaglutide vs other GLP-1 options in 2026
Semaglutide is not the only GLP-1 you can compound, and not always the right one. Tirzepatide tends to outperform it in head-to-head trials and is also still available through compounded routes, with the same 2026 caveats. We cover the parallel rules in our guide to compounded tirzepatide pharmacies. Retatrutide is the next-generation triple agonist still in trials and not legally available outside investigational settings.
If you have already shopped around and the price is your main blocker, the broader breakdown lives in the cheapest GLP-1 options in 2026. If you want a closer look at how telehealth fits the picture, including the platforms above and a few alternatives, see the telehealth GLP-1 guide.
Frequently Asked Questions
Frequently Asked Questions
Medical disclaimer: This article is for educational purposes only and does not constitute medical advice. Compounded semaglutide is a prescription medication. Talk to a licensed healthcare provider before starting, switching, or stopping any GLP-1 therapy. Regulatory information reflects FDA guidance as of May 8, 2026 and may change.